S

Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399

Watchlist Manager
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Watchlist
Price: 10.8 CNY -5.1% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
Shenzhen Hepalink Pharmaceutical Group Co Ltd?
Write Note

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
Inventory
ÂĄ6B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
20%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Inventory
ÂĄ575.8m
CAGR 3-Years
24%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Inventory
ÂĄ4.5B
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Inventory
ÂĄ2.3B
CAGR 3-Years
-1%
CAGR 5-Years
11%
CAGR 10-Years
16%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Inventory
ÂĄ6B
CAGR 3-Years
-12%
CAGR 5-Years
-12%
CAGR 10-Years
2%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Inventory
ÂĄ140.9m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 2,046 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Company’s main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The firm distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.

Intrinsic Value
12.99 CNY
Undervaluation 17%
Intrinsic Value
Price
S

See Also

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Inventory?
Inventory
6B CNY

Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Inventory amounts to 6B CNY.

What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Inventory growth rate?
Inventory CAGR 10Y
20%

Over the last year, the Inventory growth was -23%. The average annual Inventory growth rates for Shenzhen Hepalink Pharmaceutical Group Co Ltd have been 13% over the past three years , 24% over the past five years , and 20% over the past ten years .

Back to Top